Results 131 to 140 of about 125,630 (314)
ABSTRACT Allergic rhinitis (AR) is a chronic inflammatory disease of the nasal mucosa characterized by allergen sensitization and the involvement of multiple inflammatory mediators. Currently, the treatment of AR mainly includes symptomatic relief, anti‐inflammatory therapy, and nerve desensitization. However, these treatments have limitations in fully
Yue Gu +7 more
wiley +1 more source
Cornulin, a marker of late epidermal differentiation, is down‐regulated in eczema
Agne Liedén +16 more
openalex +2 more sources
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki +24 more
wiley +1 more source
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory disease characterized by recurrent remissions and relapses. Topical anti‐inflammatory steroids are commonly used for treatment, but their long‐term use poses concerns because of potential side effects. Delgocitinib ointment, a Janus kinase inhibitor, has demonstrated efficacy in several clinical
Masatoshi Abe +5 more
wiley +1 more source
Nargile (Hubble‐Bubble) smoking‐induced hand eczema [PDF]
Meltem Önder +2 more
openalex +1 more source
ABSTRACT Accurate diagnosis is essential for timely intervention in atopic dermatitis (AD), yet delays in diagnosis remain common. To better understand current clinical practices regarding infantile AD, a questionnaire survey was conducted among Japanese pediatricians working at medical institutions with 19 or fewer beds.
Kiwako Yamamoto‐Hanada +6 more
wiley +1 more source
Interactive Effects of Genetic Susceptibility and Early-Life Tobacco Smoke Exposure on the Asthma-Eczema Complex Phenotype in Children: 6-Year Follow-Up Case-Control Study. [PDF]
Dębińska A +3 more
europepmc +1 more source

